Erin Van Winkle

1.1k total citations
9 papers, 88 citations indexed

About

Erin Van Winkle is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erin Van Winkle has authored 9 papers receiving a total of 88 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erin Van Winkle's work include CAR-T cell therapy research (9 papers), Immunotherapy and Immune Responses (7 papers) and Sarcoma Diagnosis and Treatment (4 papers). Erin Van Winkle is often cited by papers focused on CAR-T cell therapy research (9 papers), Immunotherapy and Immune Responses (7 papers) and Sarcoma Diagnosis and Treatment (4 papers). Erin Van Winkle collaborates with scholars based in United States, Spain and France. Erin Van Winkle's co-authors include Elliot Norry, Dejka M. Araujo, Sandra P. D’Angelo, Brian Andrew Van Tine, Dennis Williams, Albiruni Ryan Abdul Razak, Sandra J. Strauss, Jean‐Yves Blay, Steven Attia and Trupti Trivedi and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and ESMO Open.

In The Last Decade

Erin Van Winkle

8 papers receiving 84 citations

Peers

Erin Van Winkle

ONCOL

PRM

IMMUN

GENET

Karen Howe United Kingdom

Stephanie Xavier United States

Andrea Mayer-Mokler Germany

Orenthial J. Fulbright United States

Elena J. Orlando United States

Barchuk As Russia

Enyu Dai United States

Tasha Tsao United States

Amy Marshall United States

Ouiam Bakkacha United States

Karen Howe United Kingdom

Erin Van Winkle

63 ×0.8

ONCOL

23 ×0.5

PRM

52 ×1.4

IMMUN

20 ×1.0

GENET

11 ×1.0

Citations per year, relative to Erin Van Winkle Erin Van Winkle (= 1×) peers Karen Howe

Countries citing papers authored by Erin Van Winkle

Since Specialization

Citations

This map shows the geographic impact of Erin Van Winkle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Van Winkle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Van Winkle more than expected).

Fields of papers citing papers by Erin Van Winkle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Van Winkle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Van Winkle. The network helps show where Erin Van Winkle may publish in the future.

Co-authorship network of co-authors of Erin Van Winkle

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Van Winkle. A scholar is included among the top collaborators of Erin Van Winkle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Van Winkle. Erin Van Winkle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

D’Angelo, Sandra P., Mihaela Druta, Brian A. Van Tine, et al.. (2025). Long-Term Survival of Patients with Advanced/Metastatic Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Who Received the T-Cell Receptor T-Cell Therapy, Afamitresgene Autoleucel, in the Phase 2 Spearhead-1 Trial. Transplantation and Cellular Therapy. 31(2). S250–S250.

Wagner, Michael J., Dejka M. Araujo, Jean‐Yves Blay, et al.. (2024). 54O Health state impacts of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell liposarcoma: SPEARHEAD-1 cohort 1. ESMO Open. 9. 102444–102444. 1 indexed citations

Tine, Brian Andrew Van, Kristen N. Ganjoo, Jean‐Yves Blay, et al.. (2023). The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11563–11563. 8 indexed citations

D’Angelo, Sandra P., Steven Attia, Jean‐Yves Blay, et al.. (2022). Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.. Journal of Clinical Oncology. 40(16_suppl). 11562–11562. 12 indexed citations

D’Angelo, Sandra P., Brian Andrew Van Tine, Steven Attia, et al.. (2021). SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.. Journal of Clinical Oncology. 39(15_suppl). 11504–11504. 31 indexed citations

Araujo, Dejka M., Mihaela Druta, Mark Agulnik, et al.. (2020). SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.. Journal of Clinical Oncology. 38(15_suppl). TPS11569–TPS11569. 10 indexed citations

Hong, David S., Marcus O. Butler, Anthony J. Olszanski, et al.. (2018). Initial safety assessment of MAGE-A4 SPEAR T-cells. Annals of Oncology. 29. viii412–viii412. 4 indexed citations

Odunsi, Kunle, Mihaela Cristea, Oliver Dorigo, et al.. (2017). A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).. Journal of Clinical Oncology. 35(15_suppl). TPS3094–TPS3094. 4 indexed citations

Mackall, Crystal L., William D. Tap, John Glod, et al.. (2017). Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^c259t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. Journal of Clinical Oncology. 35(15_suppl). 3000–3000. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact